Payers like key traits of pragmatic clinical trials, but are wary of pharmaceutical companies and plan to carefully scrutinize this new, appealing type of evidence.
Jonathan Ratner, PhD
Advertisement
Articles by Jonathan Ratner, PhD
Advertisement
Latest Updated Articles
- Pragmatic Clinical Trials: US Payers' Views on Their Value
Published: May 10th 2013 | Updated:
Advertisement
Advertisement
Trending on AJMC
1
New Legislation Aims to Address Transparency in PBMs as First Major Step in Reform
2
Advances in MASLD and MASH Care Highlight Progress and Persistent Gaps
3
Catchment Areas Shape Diversity and Access in Oncology Trials: Amir Fathi, MD
4
Overcoming Mistrust in Clinical Trial Enrollment Through Community Resources: Susan Vadaparampil, PhD, MPH
5